News Impax buys Teva and Allergan generics for $586 million Teva must sell some assets before buying Allergan's generics business.
News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
Articles Teva: looking for innovation and growth in ‘space between’ b... Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.